Insider · CIK 0001914883
Robin Shane Readnour
director
Files at ANTX (AN2 Therapeutics, Inc.). First filing Nov 21, 2024, latest Sep 11, 2026.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
3 / 2
$406k bought, $104k sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ANTX: AN2 Therapeutics, Inc.
ANTXOct 9, 2026 · close 4.40
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 3Weak | AN2 Therapeutics, Inc. | $6,675 1,108 shares | -0% | +456% from low-9% from high | |
| 13Weak | AN2 Therapeutics, Inc. | $97k 16,119 shares | -3% | +478% from low-5% from high | |
| 40Moderate | AN2 Therapeutics, Inc. | $87k 60,000 shares | +11% | - | |
| 48Moderate | AN2 Therapeutics, Inc. | $106k 75,000 shares | +15% | - | |
| 48Moderate | AN2 Therapeutics, Inc. | $213k 200,000 shares | +41% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 9, 2026 | ANTX AN2 Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnotes10b5-1 | -523 | $6.02 | $3,151 | 557,467 | 31 d ago |
| Sep 9, 2026 | ANTX AN2 Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnotes10b5-1 | -585 | $6.02 | $3,524 | 624,765 | 31 d ago |
| Sep 3, 2026 | ANTX AN2 Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnotes10b5-1 | -2,877 | $6.07 | $17k | 562,715 | 34 d ago |
| Sep 3, 2026 | ANTX AN2 Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnotes10b5-1 | -3,223 | $6.07 | $20k | 630,644 | 34 d ago |
| Sep 8, 2026 | ANTX AN2 Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnotes10b5-1 | -4,725 | $6.02 | $28k | 557,990 | 34 d ago |
| Sep 8, 2026 | ANTX AN2 Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See footnotes10b5-1 | -5,294 | $6.02 | $32k | 625,350 | 34 d ago |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +20,724 | - | - | 20,724 | Mar 23, 2026 |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -20,724 | - | - | 0 | Mar 23, 2026 |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +23,742 | - | - | 23,742 | Mar 23, 2026 |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -23,742 | - | - | 0 | Mar 23, 2026 |
| Feb 20, 2026 | ANTX AN2 Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +20,400 | $0.00 | $0 | 20,400 | Feb 23, 2026 |
| May 22, 2025 | ANTX AN2 Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +19,111 | $0.00 | $0 | 19,111 | May 23, 2025 |
| Dec 19, 2024 | ANTX AN2 Therapeutics, Inc. | AGrant or award Common Stock | +9,077 | $0.00 | $0 | 9,077 | Dec 23, 2024 |
| Dec 6, 2024 | ANTX AN2 Therapeutics, Inc. | POpen-market purchase Common Stockindirect: See Footnote | +12,711 | $1.45 | $18k | 564,999 | Dec 10, 2024 |
| Dec 6, 2024 | ANTX AN2 Therapeutics, Inc. | POpen-market purchase Common Stockindirect: See Footnote | +6,517 | $1.45 | $9,427 | 629,090 | Dec 10, 2024 |
| Dec 9, 2024 | ANTX AN2 Therapeutics, Inc. | POpen-market purchase Common Stockindirect: See Footnote | +12,289 | $1.43 | $18k | 577,288 | Dec 10, 2024 |
| Dec 9, 2024 | ANTX AN2 Therapeutics, Inc. | POpen-market purchase Common Stockindirect: See Footnote | +18,483 | $1.43 | $26k | 647,573 | Dec 10, 2024 |
| Dec 10, 2024 | ANTX AN2 Therapeutics, Inc. | POpen-market purchase Common Stockindirect: See Footnote | +5,000 | $1.49 | $7,462 | 582,288 | Dec 10, 2024 |
| Dec 10, 2024 | ANTX AN2 Therapeutics, Inc. | POpen-market purchase Common Stockindirect: See Footnote | +5,000 | $1.49 | $7,468 | 652,573 | Dec 10, 2024 |
| Nov 26, 2024 | ANTX AN2 Therapeutics, Inc. | POpen-market purchase Common Stockindirect: See Footnote | +12,500 | $1.39 | $17k | 527,288 | Nov 27, 2024 |
| Nov 26, 2024 | ANTX AN2 Therapeutics, Inc. | POpen-market purchase Common Stockindirect: See Footnote | +12,500 | $1.39 | $17k | 597,573 | Nov 27, 2024 |
| Nov 27, 2024 | ANTX AN2 Therapeutics, Inc. | POpen-market purchase Common Stockindirect: See Footnote | +25,000 | $1.42 | $35k | 552,288 | Nov 27, 2024 |
| Nov 27, 2024 | ANTX AN2 Therapeutics, Inc. | POpen-market purchase Common Stockindirect: See Footnote | +25,000 | $1.42 | $35k | 622,573 | Nov 27, 2024 |
| Nov 19, 2024 | ANTX AN2 Therapeutics, Inc. | POpen-market purchase Common Stockindirect: See Footnote | +75,000 | $1.03 | $78k | 560,073 | Nov 21, 2024 |
| Nov 19, 2024 | ANTX AN2 Therapeutics, Inc. | POpen-market purchase Common Stockindirect: See Footnote | +75,000 | $1.04 | $78k | 489,788 | Nov 21, 2024 |
| Nov 20, 2024 | ANTX AN2 Therapeutics, Inc. | POpen-market purchase Common Stockindirect: See Footnote | +25,000 | $1.16 | $29k | 585,073 | Nov 21, 2024 |
| Nov 20, 2024 | ANTX AN2 Therapeutics, Inc. | POpen-market purchase Common Stockindirect: See Footnote | +25,000 | $1.15 | $29k | 514,788 | Nov 21, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.